Public Market Listing
185750KOSPI
Live quotes, historical charts, and market capitalization for Chong Kun Dang Pharmaceutical are available on Yahoo Finance.
View quote & market cap on Yahoo Finance ↗External market data link · No third-party exchange redistribution
Assets
(7 total)
7Total Assets
0Approved
2Phase 3 / Filed
5Phase 1–2 / Early
7Diseases
Quick filter:
| Target & Modality | |||
|---|---|---|---|
CKD-701No recent activity | Phase 3 | VEGF-AMonoclonal antibody | Age-Related Macular Degeneration |
Lobeglitazone(Duvie) | Phase 3 | PPAR-gammaSmall molecule | Type 2 DiabetesMASH / NASH |
CKD-506No recent activity | Phase 2 | HDAC6 (Histone deacetylase 6) | Rheumatoid Arthritis |
| Phase 1/2 | METAntibody–drug conjugate | Non-Small Cell Lung Cancer | |
CKD-385No recent activity | Phase 1 | Undisclosed / early pipelineSmall molecule | Hypertension |
| Phase 1 | IL-4R-alphaMonoclonal antibody | Atopic Dermatitis | |
tofacitinib (Chong Kun Dang)No recent activity | Phase 1 | JAK1 / JAK3Small molecule | Rheumatoid Arthritis |
Upcoming events
Research
Unlock the company readout calendar
Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.
Financial reports
Research
Unlock sourced financial history
Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.